These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 33130441)

  • 21. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy.
    Duan X; Zhao F; Shang X; Yue J; Chen C; Ma Z; Chen Z; Zhang C; Pang Q; Zhang W; Abbas AE; Jiang H
    Cancer Med; 2024 Aug; 13(15):e70113. PubMed ID: 39136674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data.
    Rice TW; Lerut TE; Orringer MB; Chen LQ; Hofstetter WL; Smithers BM; Rusch VW; van Lanschot J; Chen KN; Davies AR; D'Journo XB; Kesler KA; Luketich JD; Ferguson MK; Räsänen JV; van Hillegersberg R; Fang W; Durand L; Allum WH; Cecconello I; Cerfolio RJ; Pera M; Griffin SM; Burger R; Liu JF; Allen MS; Law S; Watson TJ; Darling GE; Scott WJ; Duranceau A; Denlinger CE; Schipper PH; Ishwaran H; Apperson-Hansen C; DiPaola LM; Semple ME; Blackstone EH
    Dis Esophagus; 2016 Oct; 29(7):715-723. PubMed ID: 27731548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of pathologic response and survival outcomes between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant immunochemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma: a propensity score-matched analysis.
    Wang Y; Ma K; Zhang H; Wu L; Liu L; Zhou Y; Peng L; Wang Q; Zhuang X
    BMC Cancer; 2024 Oct; 24(1):1228. PubMed ID: 39369225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Zhang J; Peng L; Wang Q
    BMC Cancer; 2024 Aug; 24(1):945. PubMed ID: 39095767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
    J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.
    Wang J; Wu N; Zheng QF; Yan S; Lv C; Li SL; Yang Y
    World J Gastroenterol; 2014 Dec; 20(48):18397-403. PubMed ID: 25561808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
    Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
    BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma.
    Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
    Ann Surg Oncol; 2019 Dec; 26(13):4737-4743. PubMed ID: 31414291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Chen SB; Wang X; Chen YP
    Cancer Control; 2024; 31():10732748241284905. PubMed ID: 39259832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
    Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
    Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study.
    Zhong Q; Chen QY; Parisi A; Ma YB; Lin GT; Desiderio J; Yan S; Xie JW; Wang JB; Hou JF; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Liu ZY; Que SJ; Li P; Zheng CH; Huang CM
    Oncologist; 2021 Jan; 26(1):e99-e110. PubMed ID: 32864840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
    Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
    BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of the 8th edition of the AJCC yTNM staging system shows improved prognostication in a single center cohort of esophageal carcinomas.
    Kröll D; Noser L; Erdem S; Storni F; Arnold D; Dislich B; Zlobec I; Candinas D; Seiler CA; Langer R
    Surg Oncol; 2018 Mar; 27(1):100-105. PubMed ID: 29549896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of perineural invasion as a histopathological prognostic factor in ypStage II/III oesophageal squamous cell carcinoma†.
    Hsu PK; Chien LI; Lin CH; Yeh YC; Chuang CY; Hsu HS; Wu YC; Hsu CP
    Eur J Cardiothorac Surg; 2019 May; 55(5):927-933. PubMed ID: 30496377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.
    Li J; Zhou X; Liu Y; Zhu J; Wan G; Wang Y; Leng X; Han Y; Peng L; Wu L; Wang Q
    Ann Surg Oncol; 2024 Jun; 31(6):3803-3812. PubMed ID: 38280959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proposal of New ypStage Grouping System for Esophageal Squamous Cell Carcinoma Patients who Underwent Neoadjuvant Chemoradiotherapy followed by Surgery.
    Park SY; Park B; Yun JK; Kim HR; Kim YH; Jeon YJ; Lee J; Cho JH; Choi YS; Zo JI; Shim YM; Kim HK
    Ann Surg; 2024 Jan; ():. PubMed ID: 38230528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.